Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cluster of Differentiation 228 (CD228)
- Target
- CD228
- Molecular classification
- Glycoprotein, Glycophosphatidylinositol (GPI)-anchored membrane protein, Transferrin superfamily
01
Overview
CD228/melanotransferrin is a transferrin family member highly expressed on several solid tumors but minimally present on most normal adult tissues. Its biological roles include promoting angiogenesis and possibly facilitating metastasis. These features make it an appealing target for novel immunotherapies—including ADCs and bispecific agents—currently under clinical investigation for multiple cancers.
- Other names
- MelanotransferrinMELTFMFI2p97
02
Mechanism of action
Bispecific molecules like SGN-BB228 bind both CD228 on tumor cells and activate costimulatory receptors like 4‑1BB on T cells, leading to enhanced T-cell cytotoxicity localized at sites where tumor cells express high levels of CD228.
03
Biological functions
Endothelial cell migrationAngiogenesisPlasminogen activationCellular differentiationTumor proliferationTumor migration
04
Disease associations
CancerMelanomaNon-small cell lung cancer (NSCLC)Triple-negative breast cancer (TNBC)Colorectal cancerPancreatic cancerMesotheliomaAlzheimer’s diseaseArthritis
05
Safety considerations
Potential off-tumor effects due to low normal tissue expression, although bispecifics aim to minimize this.Risk of systemic immune activation with immunotherapies.
06
Interacting drugs
Antibody-drug conjugates (ADCs) targeting CD228
1 more in the full profile.
07
Biomarkers
Soluble CD228
Beyond the preview
Go deeper on Cluster of Differentiation 228 (CD228).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cluster of Differentiation 228 (CD228).